SCHEMBL3010426

SCHEMBL3010426

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(Cc4cccc(C)c4C)cs3)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
MAPT P10636 3/20 0.61
RECQL P46063 2/20 0.61
L3MBTL1 Q9Y468 3/20 0.55
HTT P42858 3/20 0.55
USP2 O75604 2/20 0.55
LMNA P02545 1/20 0.55
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.46
MAPK1 P28482 1/20 0.46
HTR6 P50406 1/20 0.44
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009456 0.93 MAPT (0.52) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3006233 0.93 ALDH1A1 (0.61) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3019130 0.92 ALDH1A1 (0.49) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3010666 0.91 ALDH1A1 (0.48) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3014655 0.91 ALDH1A1 (0.64) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3017807 0.90 ALDH1A1 (0.61) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3012014 0.89 ALDH1A1 (0.56) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3645891 0.88 ALDH1A1 (0.46) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3014595 0.88 ALDH1A1 (0.55) ALDH1A1MAPTRECQLL3MBTL1HTT
SCHEMBL3017986 0.87 ALDH1A1 (0.55) ALDH1A1MAPTRECQLL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.